Strategies to Optimize Treatment for Locally Advanced Rectal Cancer.
Xiaoyu HuZhuang XueKewen HeYaru TianYu ChenMengyu ZhaoJinming YuJinbo YuePublished in: Cancers (2022)
Neoadjuvant long-course concurrent chemoradiation plus surgery, followed by optional adjuvant chemotherapy, is a standard of care for locally advanced rectal cancer (LARC). However, this traditional approach has several limitations, including low pathological complete response (pCR) (10-25%), high metastasis rate (30-35%), and highly inconsistent compliance with adjuvant chemotherapy (25-75%). Treatment modalities for LARC have dramatically evolved in recent years. Multiple clinical trials have focused on optimizing strategies to achieve a win-win situation for oncologic outcomes and functions. Here, we review the latest studies into optimizing neoadjuvant treatment for LARC.
Keyphrases
- rectal cancer
- locally advanced
- clinical trial
- healthcare
- prostate cancer
- lymph node
- minimally invasive
- randomized controlled trial
- radiation therapy
- type diabetes
- palliative care
- coronary artery disease
- metabolic syndrome
- replacement therapy
- open label
- acute coronary syndrome
- study protocol
- smoking cessation
- percutaneous coronary intervention